Dr Reddy's Labs launches fosaprepitant for injection in US market
Dr Reddy's Laboratories Ltd announced launch of fosaprepitant for injection the therapeutic generic equivalent of US FDA approved Emend (fosaprepitant) for injection in the US market.
"We are pleased to be among the first generics to launch this product," explained Marc Kikuchi, chief executive officer, North America Generics, Dr.Reddy's Laboratories.
"This is a great addition to our injectable portfolio in the US market, as we continue to augment our product offering and drive growth for the hospital segment," added Kikuchi.
The Emend for Injection brand had sales of approximately US$ 279 million Moving Annual Total (MAT) for the most recent twelve months ending in July 2019, according to IQVIA Health.
Dr. Reddy's Laboratories Ltd has a portfolio of products and services including active pharmaceutical ingredient (APls), custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.